PVT-401 / Parvus Therap - LARVOL DELTA

A Phase 1 Study of PVT401 in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Parvus Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Phase 1 Study of PVT401 in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Parvus Therapeutics, Inc.

First-in-human • New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD (Businesswire) - "National Resilience, Inc...today announced the expansion of its collaboration with Parvus Therapeutics ('Parvus') to support the development and manufacturing their second novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease (IBD)."

Licensing / partnership • Inflammatory Bowel Disease